Bernardino Ghetti , Pedro Piccardo , Blas Frangione , Orso Bugiani , Giorgio Giaccone , Katherine Young , Frances Prelli , Martin R. Farlow , Stephen R. Dlouhy , Fabrizio Tagliavini
{"title":"Prion protein hereditary amyloidosis: parenchymal and vascular","authors":"Bernardino Ghetti , Pedro Piccardo , Blas Frangione , Orso Bugiani , Giorgio Giaccone , Katherine Young , Frances Prelli , Martin R. Farlow , Stephen R. Dlouhy , Fabrizio Tagliavini","doi":"10.1006/smvy.1996.0024","DOIUrl":null,"url":null,"abstract":"<div><p>Prion protein (PrP) amyloidosis is a feature of Gerstmann-Sträussler-Scheinker disease (GSS) and prion protein cerebral amyloid angiopathy (PrP-CAA). GSS and PrP-CAA are associated with point mutations of the prion protein gene (PRNP); there is a broad spectrum of clinical presentations and the main signs are ataxia, spastic paraparesis, extrapyramidal signs and dementia. In GSS, parenchymal amyloid may be associated with spongiform changes or neurofibrillary lesions; in PrP-CAA, vascular amyloid is associated with neurofibrillary lesions. In the two diseases, a major component of the amyloid fibrils is a 7 kDa peptide, approximately spanning residues 81–150 of PrP.</p></div>","PeriodicalId":92955,"journal":{"name":"Seminars in virology","volume":"7 3","pages":"Pages 189-200"},"PeriodicalIF":0.0000,"publicationDate":"1996-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1006/smvy.1996.0024","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in virology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1044577396900244","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11
Abstract
Prion protein (PrP) amyloidosis is a feature of Gerstmann-Sträussler-Scheinker disease (GSS) and prion protein cerebral amyloid angiopathy (PrP-CAA). GSS and PrP-CAA are associated with point mutations of the prion protein gene (PRNP); there is a broad spectrum of clinical presentations and the main signs are ataxia, spastic paraparesis, extrapyramidal signs and dementia. In GSS, parenchymal amyloid may be associated with spongiform changes or neurofibrillary lesions; in PrP-CAA, vascular amyloid is associated with neurofibrillary lesions. In the two diseases, a major component of the amyloid fibrils is a 7 kDa peptide, approximately spanning residues 81–150 of PrP.